ReviewCancer management and research2025
Study on Risk Factors and Treatment Strategies for Deep Vein Thrombosis in Patients with Multiple Myeloma.
Review in Cancer management and research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- MiR-503-5p as a potential biomarker for deep venous thrombosis (DVT) in multiple myeloma (MM) and its role in disease development.Annals of hematology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Multiple myeloma (MM) is a malignant tumor originating from plasma cells, and in recent years, its incidence has shown a significant upward trend in our country. Venous thromboembolism (VTE) is a relatively common complication in multiple myeloma (MM) patients. Venous thromboembolism includes deep vein thrombosis (DVT) and pulmonary embolism (PE), with patients facing a high risk of DVT during treatment. Studies have shown that the procoagulant state of MM, inflammatory response, and the therapeutic drugs used significantly increase the incidence of DVT. However, the exact mechanisms behind the increased risk of venous thrombosis are not yet fully understood. The occurrence of DVT not only has a severely negative impact on patient survival rates but also leads to adjustments in treatment plans and a reduction in patients' quality of life. This article analyzes the relationship between risk factors for DVT and MM, exploring current diagnostic methods, risk assessment tools, and personalized preventive treatment strategies, ultimately proposing future research directions. Through a review and analysis of relevant literature, it aims to enhance the understanding of multiple myeloma and deep vein thrombosis, providing references for clinical diagnosis and treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.